Study of morphine-induced dependence in gonadectomized male and female mice

Sadeghi, Mahsa; Sianati, Setareh; Anaraki, Dina Kalbasi; Ghasemi, Mehdi; Javadi‐Paydar, Mehrak; Sharif, Behrang; Mehr, Shahram Ejtemaei; Dehpour, Ahmad Reza

doi:10.1016/j.pbb.2008.09.015

Cited by 16 publications

(8 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results agree with the previous finding showing that naloxone-precipitated withdrawal syndrome is similar in male and female rats (7). Moreover, data obtained from mice support the previous findings that female mice are less prone to developing signs of naloxone withdrawal syndrome than male animals (5,35).…”

Section: Discussionsupporting

confidence: 93%

“…In contrast, M-10/50 female mice did not show withdrawal signs, and M-20/100 female mice had less severe withdrawal (only jumping) in respect to M-20/100 males. Studies on sex-related differences in the expression of morphine withdrawal syndrome precipitated by naloxone have produced inconsistent results both in rats (4,7) and in mice (5,6,11,35). Our results agree with the previous finding showing that naloxone-precipitated withdrawal syndrome is similar in male and female rats (7).…”

Section: Discussionsupporting

confidence: 81%

“…Several withdrawal signs have been observed following naloxone challenge in morphine-dependent animals (5,6,11,16,30,31). Weight loss and jumping are considered predominant signs for quantification of naloxone withdrawal in both rats (33,34) and mice (6,11,35). Accordingly, naloxone precipitated withdrawal weight loss and jumping in morphine-treated male and female rats (Figures 1 and 2).…”

Section: Discussionmentioning

confidence: 97%

See 2 more Smart Citations

Spontaneous withdrawal in intermittent morphine administration in rats and mice: effect of clonidine coadministration and sex-related differences

ALLAHVERDİYEV¹,

TÜRKMEN²,

NURTEN³

et al. 2015

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Treating animals repeatedly with intermittent and increasing morphine doses has been suggested to allow some withdrawal during each dosing interval, which causes repeated stress. The present study aimed to test this hypothesis and assess sexrelated differences in withdrawal signs and their suppression by clonidine.Materials and methods: Male and female rats and mice were administered with increasing doses of morphine twice daily at different dosing intervals. Rats were given clonidine in drinking water (5 µg/mL). Spontaneous and naloxone-precipitated withdrawal signs and novelty-induced grooming were evaluated.Results: Male rats and male and female rats displayed manifestations of morphine withdrawal at the end of 14-h and 24-h dosing intervals, respectively. Clonidine attenuated the severity of the withdrawal signs. Male but not female mice displayed withdrawal signs at the end of 12-h and 17-h dosing intervals. Female mice exhibited less pronounced naloxone-precipitated withdrawal syndrome. Grooming did not reflect a "stress-like state" in morphine-treated animals. Conclusion:These findings indicate intermittent morphine treatment-induced spontaneous withdrawal in rats and mice and sexrelated differences in spontaneous and naloxone-precipitated withdrawal signs in mice. Since the treatment protocol closely parallels the drug use pattern in opioid addicts, further experiments are needed to clarify the stress associated with the treatment and the efficacy of sedatives.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Spontaneous withdrawal in intermittent morphine administration in rats and mice: effect of clonidine coadministration and sex-related differences

ALLAHVERDİYEV¹,

TÜRKMEN²,

NURTEN³

et al. 2015

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…Lending further support for this premise, treatment with the androgen receptor antagonist, flutamide, attenuates naloxone-precipitated withdrawal in morphine-treated male rats (Nayebi & Rezazadeh, 2008). Similarly, castration attenuates naloxone-precipitated withdrawal in morphine-treated male rodents, and this effect is blocked by supplemental treatment with testosterone (Nayebi & Rezazadeh, 2008;Sadeghi et al, 2009). In contrast, both acute and chronic treatment with finasteride decreases naloxone-precipitated opioid withdrawal in morphine-treated male rats (Verdi & Ahmadiani, 2007).…”

Section: Animalsmentioning

confidence: 89%

“…Chronic treatment with androgens generally increases the severity of naloxone-precipitated withdrawal in morphine-treated male and female rodents (Célérier et al, 2003;Nayebi & Rezazadeh, 2008;Sadeghi et al, 2009;Philipova et al, 2003), suggesting that androgens increase the severity of opioid-induced physical dependence. Lending further support for this premise, treatment with the androgen receptor antagonist, flutamide, attenuates naloxone-precipitated withdrawal in morphine-treated male rats (Nayebi & Rezazadeh, 2008).…”

Section: Animalsmentioning

confidence: 98%

Sex Differences in Opioid-Mediated Effects: Role of Androgens

Sharp

Pearson

Smith

2020

Preprint

View full text Add to dashboard Cite

An abundance of data indicate there are sex differences in endogenous opioid peptides and opioid receptors, leading to functional differences in sensitivity to opioid-mediated behaviors between males and females. Many of these sex differences are mediated by the effects of gonadal hormones on the endogenous opioid system. Whereas much research has examined the role of ovarian hormones on opioid-mediated endpoints, comparatively less research has examined the role of androgens. This review describes what is currently known regarding the influence of androgens on opioid-mediated endpoints and how androgens may contribute to sex differences in opioid-mediated effects. The review also addresses the clinical implications of androgenic modulation of opioid-mediated behaviors and suggests future lines of research for preclinical and clinical investigators, We conclude that further investigation into androgenic modulation of opioid-mediated effects may lead to new options for addressing conditions such as chronic pain and substance use disorders.

show abstract